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Abstract: 
 
A new malbrancheamide analogue, isomalbrancheamide B (3), along with three known 
compounds, malbrancheamide (1), isomalbrancheamide (2), and premalbrancheamide (4), were 
isolated in higher yields from the alkaloid fraction of the fungus Malbranchea aurantiaca. The 
interaction of the alkaloids 1–4 with calmodulin (CaM) was analyzed using different enzymatic, 
fluorescence, spectroscopic, nuclear magnetic resonance (NMR), and molecular modelling 
techniques. On the basis of the enzymatic and fluorescence experiments, malbrancheamides 1–
3 are classical CaM inhibitors. Compound 4, however, did not quench the extrinsic fluorescence 
of the CaM biosensor indicating that it could be a functional inhibitor. Circular dichroism, NMR, 
and molecular modelling studies revealed that 1 binds to CaM in the same hydrophobic pocket 
than the chlorpromazine and trifluoperazine, two classical CaM inhibitors. Thus, 
malbrancheamide and related monochlorinated analogues are compounds with a high potential 
for the development of new therapeutic agents, involving CaM as their molecular target. 
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Article: 
 
Introduction 
 
Calmodulin (CaM), the primary transducer of Ca2+-mediated signals in eukaryotes, is a small 
multifunctional protein of 148 amino acids, highly conserved through evolution. The crystal 
structure of this protein revealed a dumbbell-shaped molecule with two globular domains 
connected by a flexible linker1–3. Each domain consists of two-loop-helix Ca2+-binding regions 
referred to as EF-hand structures, which expose hydrophobic surfaces. These hydrophobic 
regions interact with a large number of regulatory proteins including phosphatases, kinases, and 
ion channels. As a consequence, CaM plays an important role in muscle contraction, intracellular 
movement, DNA repair, cell proliferation, apoptosis, and short- and long-term memory, among 
other important physiological events4–6. 
 
The regulatory properties of CaM can be inhibited by a wide range of drugs and peptides, which 
modify its function by blocking its interaction with other proteins. Such is the case of the 
antipsychotics phenotiazines trifluoperazine (TFP) and chlorpromazine (CPZ), which bind to 
CaM through hydrophobic interactions with high affinity and known stoichiometry7–9. Other 
compounds, however, bind to CaM with lower specificity and uncertain stoichiometry10,11. In 
any case, CaM inhibitors might have important pharmacological repercussions thus representing 
important leads for the development of new drugs; on the other hand, the analysis of such events 
are important for the study of protein interactions and could help to understand better the 
physiological role of CaM. 
 
As part of our efforts to search for new potent and specific CaM inhibitors, we previously 
reported the isolation and structure elucidation of two novel indole alkaloids, namely 
malbrancheamide (1) and malbrancheamide B (2), from both the mycelium and culture broth of 
the fungus Malbranchea aurantiaca Sigler & Carmichael (Myxotrichaceae)12,13. Compounds 1 
and 2 inhibited the activation of the CaM-deficient-CaM-dependent cyclic adenosine 
monophosphate (cAMP) phosphodiesterase (PDE1), such as CPZ. According to a kinetic 
analysis, alkaloid 1 competitively inhibits the regulation of PDE1 by CaM in a concentration 
dependent manner. Furthermore, several structural analogues of the malbrancheamides, prepared 
while attempting the synthesis of 1 and 2, were functionally tested for their ability to inhibit 
PDE114. The relative stereochemistry at C-12a, the bicyclo[2.2.2]diazaoctane core oxidation 
state, and the indole chlorination of these analogues were found to have an important impact on 
the enzymatic activity of the complex CaM-PDE114. However, none of the tested compounds 
was more active than 1. 
 
Since 1 is a potent inhibitor of the complex CaM-PDE1, the main goal of the present 
investigation was to determine the nature of its inhibition (classical vs. functional), in solution, 
using fluorescence, circular dichroism (CD), and nuclear magnetic resonance (NMR) titration 
experiments, as well as molecular modelling studies. 
 
Materials and methods 
 
General experimental procedures 
 
Infrared (IR) spectra were taken on a Perkin-Elmer 599B spectrophotometer in KBr disks. CD 
was recorded on a JASCO J-715 spectrometer equipped with a thermostated cell-holder under 
N2 atmosphere at 37°C. 1D and 2D NMR spectra were recorded with a Varian Innova 500 or on 
a Varian Unity plus 400 spectrometers at 500 MHz (1H) or 125 MHz (13C), and 400 MHz (1H) or 
100 MHz (13C), respectively. High resolution mass spectra by fast atom bombardment (HRMS-
FAB+) were measured on a JEOL JMSAX505HA mass spectrometer. Melting points were 
obtained with a Fisher–Johns melting point apparatus and are reported uncorrected. Semi-
preparative high-performance liquid chromatography (HPLC) was performed using a Symmetry 
C18 (7 μm, 7.8 × 300 mm; Waters, Milford, MA, USA), a Nucleosil C18 (5 μm, 10 × 250 mm; 
Phenomenex, Torrance, CA, USA), or a Purospher STAR RP-18e (5 μm, 10 × 250 mm; Merck, 
Darmstadt, Germany) columns. Control of the equipment, data acquisition, processing, and 
management were performed by the Empower 2 software (Waters). Open column 
chromatography (CC) was carried out on Si-gel 60 (0.063–0.200 mm), 70-230 Mesh (Merck, 
Darmstadt, Germany). 
 
Fungal material 
 
M. aurantiaca Sigler & Carmichael (Myxotrichaceae) was collected from bat detritus in the 
Juxtlahuaca Caves, Guerrero, Mexico, in December 2002. A voucher specimen (# 24428) of M. 
aurantiaca was deposited in the mycological collection of the Laboratorio de Micopatología, 
Instituto de Biología, UNAM. 
 
Extraction and isolation 
 
Forty litres of potato dextrose broth (PDB; Difco, Detroit, MI, USA) were inoculated with 
10 cm2 agar plugs, taken from a stock culture of M. aurantiaca maintained at 4°C on potato 
dextrose agar (Difco). Culture broth was incubated at room temperature for 30 days. After 
incubation, the fermented whole broth (40 L) was filtered through cheesecloth to separate into 
supernatant and mycelia. The former was extracted exhaustively with CH2Cl2 (3 × 40 L). The 
combined organic phase was dried over anhydrous Na2SO4 and concentrated in vacuo to give a 
dark brown solid (9 g). The mycelium was macerated with CH2Cl2 (3 × 10 L). After evaporating 
the solvent in vacuo, 12.0 g of combined mycelia and culture extract were obtained. Six grams of 
the extract were subjected to Si-gel CC with a hexane-CH2Cl2-MeOH gradient to yield 19 
primary fractions (F1-F19). Fraction F14 (312 mg) was further resolved by preparative HPLC 
(Symmetry C18, MeCN, flow rate 2.0 mL/min) to yield compounds 1 (93.4 mg; RT 6.1 min), 
4 (8.0 mg; RT 5.0 min), and a mixture of 2 and 3 (47.6 mg). The latter was separated on a 
Nucleosil C18 column eluting with MeOH (flow rate 3.5 mL/min) to afford pure compounds 2 
(30.0 mg; RT 4.9 min) and 3 (5.0 mg; RT 5.3 min). The remaining part of the crude extract (6 g) 
was submitted to an acid-base treatment as follows: the extract was dissolved in CH2Cl2 (2 L) 
and extensively partitioned with HCl 1N (4 × 2 L); then, the acid extracts were basified with 
NH4OH 1N until pH 9, and extracted with CH2Cl2 (4 × 2 L). The resulting organic fractions were 
dried over Na2SO4 and concentrated in vacuo to yield 591 mg of crude alkaloidal fraction (FA). 
FA was resolved on a reverse phase Purospher STAR column eluting with MeCN (flow rate 
2.0 mL/min) to yield compounds 1 (199.2 mg; RT 7.4 min), 4 (12.4 mg; RT 5.7 min), and a 
mixture of 2 and 3 (71.1 mg). The latter was resolved using a Nucleosil C18 column eluting with 
MeOH (flow rate 2.0 mL/min) to give 2 (19.2 mg; RT 7.05 min) and 3 (40.6 mg; RT 7.6 min). 
 
Isomalbrancheamide B (3). White solid; m.p. 319–321°C; ultraviolet (UV)/vis (MeOH): 
λmax (log ϵ) = 233 (3.90), 284 (4.70) nm; IR (KBr): vmax = 3296, 2954, 2920, 1737, 1657, 1460, 
1313, and 1240 cm−1; 1H-NMR (400 MHz, MeOH-d4) δH: 7.32 (d, J = 2 Hz; H-7), 7.22 (d, J = 8.6 
Hz; H-10), 7.00 (dd, J = 2.6, 8.6 Hz; H-9), 3.42 (d, J = 10.0 Hz; H-5B), 3.05 (m; H-3A), 2.86 (m; 
H-6A), 2.85 (m; H-6B), 2.51 (m; H-1A), 2.26 (dd, J = 2.0, 10.0 Hz; H-5A), 2.15 (q, J = 2.0, 5.0 Hz; 
H-3B), 2.14 (m; H-12A), 1.99 (m; H-13A), 1.94 (m; H-13B), 1.86 (m; H-2), 1.46 (m; H-1B), 1.42 
(s; H-17), 1.32 (s; H-16); 13C-NMR (100 MHz; MeOH-d4) δC: 23.6, 24.2, 27.8, 28.2, 30.3, 30.8, 
32.6, 49.8, 52.9, 55.3, 59.5, 66.1, 104.9, 111.6, 117.9, 120.0, 123.0, 125.3, 135.6, 146.7, 176.7; 
HRMS-FAB+: m/z 369.1589, calculated for C21H24N3OCl: 369.1608. 
 
Protein purification 
 
Unlabelled and fluorescent-engineered human calmodulin (hCaM) were modified, over-
expressed, and purified from Escherichia coli strain BL21-A1, as previously described by 
González-Andrade et al.15. Uniformly 15N and 13C labelled hCaM were prepared in a salts 
minimal M9 medium containing 15NH4Cl (0.5 g/L) and 13C6-glucose (1.5 g/L), following the 
same procedure as for the unlabelled protein. 
 
PDE1 activity assay 
 
PDE1 activity was measured according to the method described by Rivero et al. with some 
modifications16. Briefly, CaM (0.08 μg) was incubated with 0.015 units of PDE1 from bovine 
brain (Sigma, St. Louis, MO, USA), during 30 min in 40 μL of assay solution containing: 0.063 
units of 5′-nucleotidase (Crotalus atrox venom; Sigma), 45 mM Tris-HCl, 5.6 mM magnesium 
acetate, 45 mM imidazole, 2.5 mM calcium chloride, and 10 mM bovine serum albumin, pH 7.0. 
Tested compounds were then added to the assay medium at 0.5, 1, 2, 3, 4, 7, 13, 20, 32, 50, and 
65 mM in MeCN-water (1:1), and the samples incubated during 30 min; thereafter 10 μL of 
10.8 mM cAMP were added to start the assay. After 15 min, the assay was stopped by the 
addition of 190 μL of malachite green solution. The amount of inorganic phosphate released was 
measured at 700 nm, and correlated with the activity of the PDE1. CPZ was used as positive 
control. All the results are expressed as the mean of at least six experiments ± SEM. The IC50 
(concentration inhibiting by 50% the activity of the enzyme) values were determined by non-
linear regression analysis by fitting to hyperbolic inhibition. 
 
Steady-state fluorescence 
 
All experiments were performed on an ISS-PC1 spectrofluorophotometer (ISS, Champaign, IL). 
Protein-specific intrinsic fluorescence of CaM (5 μM) in phosphate buffer (100 mM, pH 5.1) 
with CaCl2 (10 mM) was scanned between 400 and 550 nm at 381 nm of excitation. Each sample 
was stirred and titrated with compounds 1–4 to a different final protein/inhibitor ratio. The 
samples were contained in a 2 mL thermostat container with excitation and emission path lengths 
of 1 nm, at 37°C. Fluorescence emission spectra were acquired with excitation and emission slit 
widths of 4 and 8 nm, respectively. The apparent dissociation constant (Kd) and fractional degree 
of saturated CaM with ligand (v0) values were determined by fitting to the following second 
order equation: 
 
 
 
where P0 and L0 are the total concentrations of the protein and inhibitor, respectively, and Kd is 
the apparent dissociation constant for the ligand. CPZ was used as positive control. All data were 
analyzed using the Origin version 8.0 program (OriginLab, Northampton, MA). 
 
Circular dichroism 
 
CD was performed with samples of pure protein and complexed with the inhibitor. The 
concentration of protein used was 5 μM and ligands at saturation (100 μM), in 100 mM of 
potassium acetate (pH 5.1) at 37°C. The data were acquired with the following specifications: 
range of 200–260 nm, resolution of 1.0 nm, band width 1.0 nm, sensitivity of 100 mdeg, and 
speed of 8 nm min−1. The α-helix/β-sheet structural content of CaM, in the presence of Ca2+ and 
the inhibitors, was calculated using the K2D2 software17. 
 
NMR titration experiments 
 
All experiments were run in the Varian Innova 500 instrument equipped with a 1H, 13C, 15N TXI 
probe, by using sample tubes with a 5 mm outer diameter. Two-dimensional NMR spectra were 
recorded in the phase-sensitive mode using the States-TPPI method, and were carried out using 
the WATERGATE pulse sequence or excitation sculpting for water suppression to eliminate 
solvent signal in H2O/2H2O (95:5) solution. CaM solution (1.5 mM) was prepared in a 5% 2H2O 
solution containing 50 mM TRIS-HCl, and 10.6 mM CaCl2, and was titrated with 1 at final 
concentrations between 0 and 6 mM. 1H-13C and 1H-15N heteronuclear single quantum coherence 
(HSQC) experiments were acquired at 308 K and processed using vNMRj software (Varian Inc., 
Palo Alto, CA). 
 
Docking simulations 
 
To generate a more accurate and physically realistic model of CaM (PDB code: 1A29), several 
iterations of rebuilding and refinement, using the idealization application of Rosetta 3.1 software, 
were performed. Docking simulations of the final all-atom refinement of CaM and compound 1 
were carried out using AutoDock 4.018,19. Default parameters were used except for the number of 
GA runs (100). The protein was held rigid during the docking process while the ligand was 
allowed to be flexible. The grid box size was 60 Å × 60 Å × 60 Å in the x, y, and z dimensions, 
with the centre of the grid corresponding to the protein. FlexDock analyses were carried out 
using the residues found to 9 Å from the centre of the complex Ca2+-CaM-1 (Glu14, Phe16, 
Leu18, Phe19, Leu32, Val35, Met36, Ser38, Leu39, Met51, Phe68, Met71, Met72, Met76, 
Val91, Phe92, Leu105, Val108, Met109, Thr110, Asn111, Lau112, Glu114, Met124, Phe141, 
Met144, and Met145). The docked inhibitor-enzyme complexes were ranked according to the 
predicted binding energies and on the basis of the ideal conformation of the docked structures. 
The root-mean-square deviation (RMSD) values for each residue involved in the flexible 
docking were calculated in the RMSD software implemented in VMD 1.8.6 program. 
 
Results and discussion 
 
Reinvestigation of the extract from the mycelium and culture medium of M. aurantiaca led to the 
isolation of isomalbrancheamide B (3) [(5aS,12aS,13aS)-9-chloro-12,12-dimethyl-
2,3,11,12,12a,13-hexahydro-1H,6H 5a,13a-(epiminomethano) indolizino[7,6b]carbazol-14-one 
(3)], along with the known compounds malbrancheamide (1), malbrancheamide B (2), and 
premalbrancheamide (4) (Figure 1)13,20. Compound 4 was recently detected in the fungus culture 
by Ding et al.21 while studying the biosynthesis of 1 and 2. 
 
 
Figure 1. Structures of malbranchemide analogues. 
 
For the isolation of the malbrancheamide series, the initial extract was split in two equal parts: 
from the first one, compounds 1–4 were isolated by CC and HPLC procedures; the second, 
however, was subjected to an acid-base partition process to yield a crude FA. HPLC separation 
of FA led to the isolation of compounds 1–4 (see Supplementary Figure 1). Comparison between 
the two isolation strategies showed that the yield of 1 was significantly higher with the second 
method (5.19 vs 9.82%, respectively). 
 
Compounds 1 and 2 were characterized by comparison with authentic samples previously 
isolated from M. aurantiaca12–14, and the NMR data of 4 was consistent with the synthetic 
premalbrancheamide described by Ding et al.21. Compound 3 is a new natural product and its 
complete structural characterization was achieved using a combination of IR, CD, UV, as well as 
1D (1H and 13C-NMR) and 2D (HSQC and HMBC) NMR analyses. The molecular formula 
calculated from HRMS data was identical to that of 2 suggesting that both were isomers. The 
NMR spectra of 3 were almost identical to those of 2. The most important differences were 
observed in the 1H spectra, which in both cases displayed an ABX system for the aromatic 
protons, but as expected, their chemical shifts were different. Thus, the signals at δH 7.31 
(d, J = 8.7 Hz, H-7), 6.94 (dd, J = 8.4, 1.8 Hz, H-8), and 7.26 (d, J = 1.7 Hz, H-10) in 2, were 
replaced by signals at δH 7.32 (d, J = 2 Hz; H-7), 7.22 (d, J = 8.6 Hz; H-10), and 7.00 (dd, J = 8.6, 
2.6 Hz; H-9) in 3. The 13C-NMR spectrum (see experimental) displayed also signals for the 
bicyclo[2.2.2]diazaoctane ring system including the lactam functionality and for a 
monohalogenated indole moiety. Altogether, this information suggested that 3 was the C-9 
monochlorinated isomer of malbrancheamide B (2). 
 
Next, in order to determine if compounds 1–4 are classical or functional CaM inhibitors, 
additional experiments involving quenching of the fluorescence and CD were performed. In the 
first case, fluorescence titration curves for CaM with alkaloids 1–4 were constructed using a 
fluorescent-engineered hCaM (hCaM-M124C-mBBr) biosensor, according to the protocol 
previously described by González-Andrade et al.15. For this, Ca2+-CaM was titrated with 
different amounts of compounds 1–4 and the fluorescence changes were monitored in the range 
between 400 and 550 nm, being the maximum response at 470 nm. As shown in Figure 2, the 
fluorescence intensity of the protein changed with increasing concentrations of compounds 1−3, 
however, no significant effect was observed with 4. Thus, alkaloid 1 displayed the highest 
affinity while 4 the least. The spectral changes produced by 1−3 were attributed to the formation 
of CaM-ligand complexes; the calculated Kd values were 1.11 ± 0.08, 4.82 ± 0.30, and 
4.82 ± 0.09 μM, respectively, against the 1.43 ± 0.09 μM value observed for CPZ. The 
stoichiometry for the three alkaloids was 1:2, while for CPZ was 1:1 (Table 1). These results are 
in agreement with the enzymatic experiments carried out with Ca2+-CaM-PDE1 complex16, since 
compound 1 showed a concentration-dependent inhibitory activity of the Ca2+-CaM-PDE1 
complex (IC50 19.33 ± 1.40), whereas 2–4 displayed marginal effect (IC50 183.28 ± 37.58, 
41.56 ± 4.64, and 35.73 ± 3.01 μM, respectively). The effect of 1 was comparable with that of the 
CPZ (positive control; IC5016.78 ± 3.99 μM). 
 
 
Figure 2. Fluorescence spectra and titration curves of Ca2+-hCaM-M124C-mBBr in the presence 
of 1 (A), 2 (B), 3 (C), and 4 (D). Buffer was 100 mM of potassium acetate (pH 5.1) at 37°C and 1 mM CaCl2. 
Samples were excited at 381 nm, and emission spectra recorded for light scattering effects from 400 to 550 nm. The 
absolute changes of maximal fluorescence emission were plotted against the ration alkaloids/protein total and fitted 
to the binding equation model to obtain the Kd and stoichiometric ration. 
 
Table 1. Activity and binding properties of malbrancheamides analogues on the Ca2+-CaM complex. 
Compound IC50 (μM)a IC50 CPZ (µM)b Potencyc Kd (µM)d Stoichiometryd 
1 19.33 ± 1.40 16.78 ± 3.99 1.1 1.11 ± 0.08 2.08 ± 0.19 
2 183.28 ± 37.58 14.11 ± 1.75 0.1 4.82 ± 0.30 2.04 ± 0.63 
3 41.56 ± 4.64 14.11 ± 1.75 0.3 4.82 ± 0.09 2.37 ± 0.21 
4 35.73 ± 3.01 16.78 ± 3.99 0.5 NA NA 
CPZ, chlorpromazine; NA, not determined. 
aEnzymatic assay. 
bCPZ positive control: Kd = 1.43 ± 0.09 μM; stoichiometry = 0.69 ± 0.09. 
cPotency was obtained by the formula: IC50 (CPZ)/IC50 (compound), assuming a value of 1.00 for CPZ. 
dFluorescence experiments. 
 
Concerning the CD experiments, the folding stability of CaM in the presence of 1–4 was 
assessed measuring their far-UV CD spectra (Figure 3). According to previous analyses, the 
complex Ca2+-CaM possesses a high content of α-helix (84.2%)22,23; after addition of saturating 
concentrations of CPZ, the α-helice content decreased almost by 23% (61.3% of α-helix), 
bringing out significant changes in the secondary structure of Ca2+-CaM. The same trend of 
effects was observed after saturating the protein with 1 (68.1% of α-helix). Compounds 2 and 3 
(75.45 and 78.33% of α-helix, respectively) were less effective, and 4 did not induce any change 
(84.2% of α-helix). 
 
 
Figure 3. Far-UV circular dichroism of hCaM M124C-mBBr. in presence of 1 mM CaCl2. Buffer (−); Ca2+-hCaM 
M124C-mBBr (––); Ca2+-hCaM M124C-mBBr−1 (...); and Ca2+-hCaM M124C-mBBr−4 (–.–). The estimation of 
secondary structures from circular dichroism spectral in presence of all ligands was determined using K2D2 
program. 
 
Altogether, these results revealed that 1−3 behave as classical CaM inhibitors while 4 as 
functional inhibitor24. The latter compound did not quench the extrinsic fluorescence of the CaM 
biosensor nor modify the secondary structure of CaM according to the CD analysis. 
 
On the basis of the fluorescence and CD studies, compound 1 was selected to assess its binding 
mode to CaM. For this purpose the changes in the 1H-13C HSQC spectra upon addition of 
unlabelled 1 to uniformly 15N-13C-labelled CaM were analyzed. Compound 1 was titrated up to 
four equivalents of Ca2+-CaM. Most of the HSQC peaks of CaM were gradually shifted with 
little changes in their intensities (Figure 4). 
 
 
Figure 4. Schematic 1H-13C nuclear magnetic resonance spectra of the methyl groups of the methionine residues in 
(•) Ca2+-CaM and (○) Ca2+-CaM-1 complex. Chemical shift differences of methionines at the C-terminal (Met109, 
Met124, Met144, Met145) and N-terminal (Met36, Met51, Met71, Met72) domains of CaM, as well as the Met76 of 
the flexible linker region, are indicated with solid arrows. 
 
The resonances of Ca2+-CaM affected by 1 were situated in the methionine methyl region, 
suggesting that 1 binds to the hydrophobic pockets of the protein rich in methionines, and 
localized at the interdomain sites of CaM, regarded as T2 and T324,25. All the chemical shifts 
changes for the methionines residues 36, 51, 71, 72, 76, 109, 124, 144, and 145 were recorded 
and summarized in Table 2. 
 
Table 2. NMR and flexible docking results of the Ca2+-CaM−1 complex formation. 
Residue NMR 1H Δδ/13C Δδ (ppm) Autodock RMSD (Å) 
Met 36 0.239/0.283 0.177 
Met 51 0.342/0.650 0.606 
Met 71 0.704/0.663 0.788 
Met 72 0.079/0.649 0.857 
Met 76 0.069/0.136 1.251 
Met 109 0.226/0.070 1.263 
Met 124 0.708/0.997 0.110 
Met 144 0.919/0.585 0.996 
Met 145 0.212/0.208 0.823 
NMR, nuclear magnetic resonance; RMSD, root-mean-square deviation. 
 
Next, in order to predict the location where compound 1 binds to CaM, ligand-receptor docking 
analyses into the preferred CaM-binding pocket of TFP were performed using AutoDock 4.0, 
and the reported X-ray structure of the TFP-CaM complex (PDB code: 1A29) as template. The 
lowest free energy of binding (EFEB) of the complex 1−CaM was −9.04 kcal/mol, and the 
calculated inhibition constant (Ki) was 0.23 μM. These values are in agreement with the 
parameters of binding and activity obtained by steady-state fluorescence and enzymatic tests 
(Table 3). The refined flexible docking analysis revealed that the binding of 1 to CaM involved 
several hydrophobic interactions with the residues Glu11, Phe92, Ile100, Leu105, Met124, 
Ile125, Ala128, Val136, Phe141, and Met144, located at T2 and T3 hydrophobic pockets (Figure 
5). These residues are involved in the binding of most drugs with CaM and are located between 
the globular domains25, being their aromatic ring inside the hydrophobic area and their aliphatic 
side chains projecting towards the outside, so that the positive charge is in the acid patches. 
 
Table 3. Binding free energy (EFEB) and inhibition constant (Ki) values of compounds 1–4, obtained from the 
molecular docking analyses (AutoDock 4.0). 
Compound EFEB (Kcal/mol) Ki (µM) 
CPZa −7.82 1.85 
1 −9.04 0.23 
2 −8.58 0.51 
3 −8.56 0.53 
4 −8.04 1.27 
CPZ, chlorpromazine. 
aPositive control. 
 
 
Figure 5. Flexible docking model of the complex Ca2+-CaM−1. CaM is represented in green surface, 1 is depicted in 
purple sticks, and CPZ is shown in white lines. (A) Lowest energy AutoDock conformation of 1; (B) Residues of 
CaM (white sticks; Glu11, Phe92, Ile100, Leu105, Met124, Ile125, Ala128, Val136, Phe141, and Met144) involved 
in the complex formation. Ca2+ ions are showed in yellow balls. 
 
Conclusions 
 
Steady-state fluorescence and CD experiments, along with the enzymatic assay using CaM 
sensitive PDE1, revealed that all the alkaloids but 4 bind to Ca2+-CaM. Thus, compounds 1−3 are 
classical inhibitors, while compound 4 behaves as functional inhibitor. According to the NMR 
and docking analyses compound 1 binds to the same hydrophobic pocket than CPZ, W-7, J-8, 
and TFP. Furthermore, the docking study also indicated that the binding of 1 with the protein 
involved hydrophobic and electrostatic interactions. These observations are consistent with the 
highest affinity of compound 1 to CaM in comparison to that of 2 and 3, with one halogen in 
their structures, or 4, with no halogen in its molecule, and with not affinity at all for the protein. 
Finally, the anti-CaM properties exhibited by compound 1 are comparable to those of classical 
CaM inhibitors, and make this product a lead for the development of new drugs and a valuable 
tool for the study of the physiological role of CaM. 
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